| Astellas Seals the Deal With OSI After Rocky Courtship The Burrill Report submits: By Michael FitzhughAstellas Pharma (ALPMF.PK), Japan's second-largest drugmaker, is paying $4 billion for OSI Pharmecuticals (OSIP) and its profitable cancer medicine, Tarceva. The pricey victory is a triple-win for Astellas, likely to bolster its revenue, geographic base, and pipeline. Complete Story » seekingalpha.com |
Are Regeneron's Gout Drug Trial Results Really Bad News? Prohost Biotech submits:Regeneron’s (REGN) Phase 3 study in gout patients initiating allopurinol therapy to lower their uric acid levels showed that the company’s drug Arcalyst (rilonacept), known as IL-1 Trap, prevented gout attacks, as measured by the primary endpoint of the number of gout flares per patient over the 16 week treatment period. Is this good or bad news?Complete Story » seekingalpha.com |
Medivation, Inc. Q2 2010 Earnings Call Transcript Medivation, Inc. (MDVN)Q2 2010 Earnings Call TranscriptAugust 09, 2010 04:30 amComplete Story » seekingalpha.com |
The Fight for Market Share in Blood Thinners Is On EP Vantage submits:The latest sets of data from the new oral blood thinners, Xarelto and apixaban, presented at the European Society of Cardiology this weekend made pretty good reading for their developers. Efficacy looked solid and safety manageable, if not better than current therapies; exactly what was needed. Financial analysts expect these two agents to be generating almost $5bn by 2016, consensus data from EvaluatePharma shows. Add the similar anticoagulants also in development such as Boehringer Ingelheim’s Pradaxa and Merck & Co’s (MRK) vorapaxar and the potential market is significantly larger. The fight for market share in this high stakes arena could be hard-won. Complete Story » seekingalpha.com |
Detecting More Upside Potential for EXACT Sciences Mike Havrilla submits:With shares of EXACT Sciences (EXAS) pulling back from multi-year highs in the low $9s back to the low-mid $7s as I write this article, I am adding to my long stock position ahead of the validation study results to be presented next week. (Click here for my recent article on the merger of my site with BioRunUp.com, providing investors and traders with more resources to profit from FDA and clinical trial binary events.)Next-Generation (V3), Stool DNA (sDNA) Based Colorectal Cancer (CRC) Diagnostic Test Kit Complete Story » seekingalpha.com |